Diagnosis & Disease Information

Clofarabine plus cytarabine (Clo+Ara-C) significantly prolongs event-free survival (EFS).

Myeloid neoplasms that develop following radiation therapy differ from those arising from chemotherapy.

(ChemotherapyAdvisor) – One of the largest randomized phase 3 trials to date in patients ≥65 years of age with newly diagnosed acute myeloid leukemia (AML) has found that decitabine improved response rates compared with low-dose cytarabine or supportive care and had a possible survival advantage, according to results published in the Journal of Clinical Oncology…

A new mutation in human acute myeloid leukemia (AML) represents a valid therapeutic target.

Investigators suggest the daunorubicin/cytarabine/cladribine regimen be considered the new standard of care as remission induction.

Fractionated lower doses of gemtuzumab ozogamicin allows safe delivery of higher cumulative doses and substantially improves outcomes in adults with de novo acute myeloid leukemia (AML).